SP

Shrikant Prakash Suryavanshi

Active Director Director DIN 10684398
DIN 10684398 First appointment Jun 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Shrikant Prakash Suryavanshi

Data last updated:

Shrikant Prakash Suryavanshi is a Director at Manomay Clinical Research Institute Private Limited (since 2024).

DIN 10684398
Primary Designation Director
First Appointment 26 Jun 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Jun 20242024Active

Directorship timeline

Open interactive timeline →
Manomay Clinical Research Institute Private Limited
Premium access

Shareholding and investment profile for Shrikant Prakash Suryavanshi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shrikant Prakash Suryavanshi

Shrikant Prakash Suryavanshi currently holds 1 directorship: Manomay Clinical Research Institute Private Limited (Director, since 26 Jun 2024).

Shrikant Prakash Suryavanshi was first appointed on 26 Jun 2024 as Director at Manomay Clinical Research Institute Private Limited.

The current boards of Shrikant Prakash Suryavanshi's companies include Aastha Raj Nagarkar (Manomay Clinical Research Institute Private Limited), Prarthana Rajanish Nagarkar (Manomay Clinical Research Institute Private Limited), Viren Raj Nagarkar (Manomay Clinical Research Institute Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available